0000000000008488

AUTHOR

Edwin H. Kolodny

showing 2 related works from this author

Cerebrovascular involvement in fabry disease: current status of knowledge.

2014

Fabry disease (FD) is a rare and highly debilitating lysosomal storage disorder that results from a total lack of, or deficiency in, the enzyme α-galactosidase A (α-Gal A) because of mutations in the GLA gene.1 FD is inherited as an X-linked trait; many of the male patients develop a classic severe phenotype with early onset of symptoms, whereas heterozygous females exhibit phenotypes ranging from asymptomatic to major involvement of vital organs.2 Most families inherit private mutations; to date, >600 mutations have been identified and are listed in the online FD database (Fabry-database.org).3 The deficiency in α-Gal A causes the accumulation of globotriaosylceramide (GL-3; also abbreviat…

Pathologymedicine.medical_specialtyCell typeGlobotriaosylceramideIschemiaInflammationMuscle hypertrophychemistry.chemical_compoundFibrosisLeukoencephalopathiesInternal medicinemedicineHumansAdvanced and Specialized Nursingbusiness.industrymedicine.diseaseFabry diseasePathophysiologyStrokeCerebrovascular DisordersEndocrinologychemistryFabry DiseaseNeurology (clinical)medicine.symptomCardiology and Cardiovascular Medicinebusiness
researchProduct

A Phase III Extension Study of Aldurazyme®(Laronidase) in Mucopolysaccharidosis I

2007

PharmacologyPediatricsmedicine.medical_specialtybusiness.industryExtension studyLARONIDASEPhase (matter)Mucopolysaccharidosis IMedicineAldurazymePharmacology (medical)businessClinical Therapeutics
researchProduct